Abdalla Abotaleb
- Expert
- World Health Organisation (WHO)
- Egypt
Title :
Impact of real world data on changing treatment policies for breast cancer
Abstract :
Due to accumulation of real world data through years raised a need for health care system to use these data for enhancing, modifying, even to change policies for treatment and services. With incidence of breast cancer in low middle income country like Egypt which is the most prevalent cancer among women in Egypt, representing 18.9% of total cancer cases (35.1% in women and 2.2% in men) with an age-adjusted rate of 49.6 per 100000 populations; stages III and IV constitute 68% of all breast cancer cases. The disease leads to economic burden on budget for the health care system and raise the question how can we use real world data to enhance and modify treatment policies? Methods: Data from breast cancer patients aged (18-60 years) for the last 3 years including direct and indirect medical costs and clinical data from patients’ files and national data base. The total (n) of patients enrolled in the national database = 114684. Robustness of our findings was checked using sensitivity analyses. Results: Presence of breast cancer for the age group less than 50 years was around 45%, presence of breast cancer in Urban was 81% compared to Rural, 19 % Stage II 51% from total stages. Non-Metastatic represent 93% of sample, 30 % of expenditure was for chemotherapy compared to 23% for hormonal & 21% for targeted therapy. Conclusion: Due to incidence for premenopausal cases treatment policy should be modified to include taxanes as an optional treatment based on stages. As a result of effective awareness, early stages representing high percentage of stage 2. Treatment be regulated by stages and sub types banker cancer polices should be modified, monitored based on effective system of outcomes data.
Biography:
Abdalla Abotaleb is one of the most profound experts in healthcare policy and regulations in the MENA region His expertise extends from HTA & Reimbursement policies to regulatory and supply chain strategies in the public sector. He has been involved in the fields of health economics, outcomes research, Health policy reforming, and reimbursement policies within the healthcare industry for 15 years, with experience across the pharmaceutical, biologicals, and vaccines. And now works for WHO as a project manager at health care reforming area.
Abdalla Abotaleb graduated in faculty of pharmacy then obtained a post-graduate in health economics followed by a Ph.D. in Health Economics & Policy from York University. He also has a degree in Project Management Professional (PMP), Pharm. D certificate and a Master of Business Administration (MBA).
He, in addition to being a committee member and project manager in a number of national projects in many countries including Germany. United Kingdom, Egypt, Algeria, Sudan, Russia, UAE, Morocco, Jordan, Iraq, Turkey, KSA, GULF, USA and Poland. He is a very active researcher with tens of publication across different well-recognized organizing including ISPOR, ESMO, ASCO, ECCO, iHEA. HTAI and EuHEA. He has been a true contributor to several public and industrial projects in Egypt and the MENA region his homeland. He committedly changed the landscape of the healthcare policy there. A few examples to mention are his contributions to the establishment of the NORCB (national organization for control and research of biologics), Egyptian Biosimilars guidelines cancer and MS registry & guidelines. Establishing stroke units & guidelines, hospital-based HTA and Health economic unit at the ministry of health in Egypt’s different sectors.
Multiple engagement efforts are well recognized in his research by introducing concepts of stakeholder engagement. He also does that by being an active member of many research organizations internationally and locally like the ISPOR and its local chapter.
Abdalla Abotaleb remains a very rich source of developmental initiatives having been a hands-on expert across different sectors of the healthcare systems and a visionary for healthcare reform.